Elsevier

Metabolism

Volume 47, Issue 5, May 1998, Pages 541-548
Metabolism

Bone mineral density in prepubertal children with β-thalassemia: Correlation with growth and hormonal data

https://doi.org/10.1016/S0026-0495(98)90237-2Get rights and content

Abstract

Patients with β-thalassemia major (β-thalassemia) frequently have bone disorders of multifactorial etiology. We attempted to analyze the relationship between the bone mineral density ([BMD] measured by dual-photon absorptiometry) and auxanologic parameters, degree of siderosis, function of the growth hormone (GH)/insulin-like growth factor-I (IGF-I)/IGF-binding protein-3 (IGFBP3) axis, calcium-phosphate balance, parathyroid hormone (PTH), and cytokines (interleukin-1β [IL-1] and tumor necrosis factor-alpha [TNF-α]) in 30 prepubertal children with β-thalassemia major and 15 age-matched children with constitutional short stature (CSS), who have normal glucose tolerance and thyroid function. Children with β-thalassemia had a significantly decreased BMD and mean BMD% for age and sex (0.75 ± 0.24 g/cm2 and 71% ± 10%, respectively) versus children with CSS (1.06 ± 0.3 g/cm2 and 92% ± 7%, respectively). Thalassemic patients had significantly lower circulating concentrations of IGF-I and IGFBP3 (49 ± 21 ng/mL and 1.2 ± 0.25 mg/L, respectively) compared with control children (153 ± 42 ng/mL and 2.1 ± 0.37 mg/L, respectively). The GH response to provocation by clonidine and glucagon was defective (peak GH < 7 μg/L) in 12 of the 30 thalassemic children. Serum concentrations of IL-1β and TNF-α did not differ among the two study groups. Hypocalcemia was detected in five of the 30 thalassemic patients: hypoparathyroidism was diagnosed in two of the five and rickets in the other three. BMD was highly correlated with the circulating concentrations of IGF-I and IGFBP3, as well as with the auxanologic parameters (age, weight, height, height standard deviation score [HSDS], and body mass index [BMI]). It is suggested that increasing the circulating IGF-I concentration through aggressive nutritional therapy and/or GH/IGF-I therapy with supplementation with vitamin D and/or calcium might improve bone growth and mineralization and prevent the development of osteoporosis and consequent fractures in these patients. Such therapy requires blinded controlled trials.

References (102)

  • D Bisbocci et al.

    Osteodystrophy in thalassemia major

    Ann Ital Med Int

    (1993)
  • P Giardina

    Osteoporosis in Thalassemia

  • D Canatan et al.

    Effects of calcitonin therapy on osteoporosis in patients with thalassemia

    Acta Haematol

    (1995)
  • ML Anapliotou et al.

    The contribution of hypogonadism to the development of osteoporosis in thalassemia major: New therapeutic approach

    Clin Endocrinol (Oxf)

    (1995)
  • MAF El Hazmi et al.

    Iron-endocrine pattern in patients with β-thalassemia

    J Trop Pediatr

    (1994)
  • JB Clegg et al.

    The Thalassemia Syndrome

  • G Costin et al.

    Endocrine abnormalities in thalassemia major

    Am J Dis Child

    (1979)
  • WW Tanner et al.

    Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty

    Arch Dis Child

    (1976)
  • SW Ponder et al.

    Spinal bond mineral density in children aged 5.00 through 11.9 years

    Am J Dis Child

    (1990)
  • D Smith et al.

    Factors which influence peak bone mass formation: A study of calcium balance and the inheritance of bone mass in adolescent females

    Am J Clin Nutr

    (1990)
  • C Glastre et al.

    Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: Correlations with growth parameters

    J Clin Endocrinol Metab

    (1990)
  • JP Bonjour et al.

    Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence

    J Clin Endocrinol Metab

    (1991)
  • G Theintz et al.

    Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects

    J Clin Endocrinol Metab

    (1992)
  • V Matkovic et al.

    Timing of peak bone mass in caucasian females and its implication for the prevention of osteoporosis: Inference from cross-sectional model

    J Clin Invest

    (1994)
  • RP Heaney et al.

    Inadequate peak bone mass

  • MJ Mansfield et al.

    Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty

    J Clin Endocrinol Metab

    (1988)
  • GW Moll et al.

    Administration of low dose estrogen rapidly and directly stimulates growth hormone production

    Am J Dis Child

    (1986)
  • RN Margolis et al.

    Anabolic hormones in bone: basic research therapeutic potential

    J Clin Endocrinol Metab

    (1996)
  • L Danesi et al.

    Evaluation of hypothalamic-pituitary function in patients with thalassemia major

    J Endocrinol Invest

    (1992)
  • L Saglamer et al.

    Evaluation of growth hormone and insulin-like growth factor-I in prepubertal children with thalassemia

    Turk J Pediatr

    (1992)
  • C Pintor et al.

    Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major

    J Clin Endocrinol Metab

    (1986)
  • J Leger et al.

    Normal growth hormone response to GH-releasing hormone in children with thalassemia major before puberty: A possible age-related effect

    J Clin Endocrinol Metab

    (1989)
  • N Shehadeh et al.

    Neurosecretory dysfunction of growth hormone secretion in thalassemia major

    Acta Paediatr Scand

    (1990)
  • G Katzos et al.

    Circadian growth hormone secretion in short multitransfused prepubertal children with thalassemia major

    Eur J Pediatr

    (1995)
  • R Chatterjee et al.

    Evaluation of growth hormone in thalassemic boys with failed puberty: Spontaneous versus provocative test

    Eur J Pediatr

    (1993)
  • F Perignon et al.

    Growth and endocrine function in major thalassemia

    Arch Francaises Pediatr

    (1993)
  • MC Postel-Vinay et al.

    No evidence for a defect in growth hormone binding to liver membranes in thalassemia major

    J Clin Endocrinol Metab

    (1989)
  • KY Ho et al.

    Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man

    J Clin Invest

    (1988)
  • AT Soliman et al.

    Serum insulin-like growth factor-I and II and growth hormone and insulin response to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation

    Pediatr Res

    (1986)
  • GJ Fuchs et al.

    Nutritional factors and thalassemia major

    Arch Dis Child

    (1996)
  • L Gullo et al.

    Morphologic and functional evaluation of the exocrine pancreas in beta-thalassemia major

    Pancreas

    (1993)
  • S De Virgiliis et al.

    Serum ferritin, liver iron stores, and liver histology in children with thalassemia

    Arch Dis Child

    (1980)
  • J Bentham et al.

    Acquired growth hormone resistance in patients with hypercatabolism

    Horm Res

    (1993)
  • Soliman AT, ElBanna N, Ansari B: Growth hormone (GH) response to provocation, circulating insulin-like growth factor-I...
  • GA Werther et al.

    Lack of response of nonsuppressible insulin-like activity to short-term administration of human growth hormone in thalassemia major

    J Clin Endocrinol Metab

    (1981)
  • LC Low et al.

    Growth hormone treatment of short Chinese children with beta-thalassemia major without growth hormone deficiency

    Clin Endocrinol (oxf)

    (1995)
  • A Aynsley Green et al.

    Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism

    J Pediatr

    (1976)
  • DA Harris et al.

    Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinising hormone—releasing hormone agonist

    J Clin Endocrinol Metab

    (1985)
  • Cited by (87)

    • Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia

      2022, iScience
      Citation Excerpt :

      Disruption of both IGF1 and IGFALS genes in mice exhibited a dramatic retardation in growth (Yakar et al., 2002). In addition, a positive correlation between bone mineral density and the levels of IGF-1 and IGFBP3 in patients with β-thalassemia was observed (Lasco et al., 2002; Soliman et al., 1998). Therefore, patients with the codons 41/42 -TTCT mutation are more likely to acquire iron overload compared to patients with other mutations.

    • Chemical characterization and varying level of the proteoglycans

      2013, Carbohydrate Polymers
      Citation Excerpt :

      Decreased collagen and proteoglycan levels were closely associated with the development of osteoporosis diseases. A decrease of bone mineral density and early onset of osteoporosis have been reported in young patients (Anapliotou et al., 1995; Filosa et al., 1997; Molyvda-Athanasopoulou et al., 1999; Soliman, El Banna, Fattah, ElZalabani, & Ansari, 1998; Wonke, Hoffbrand, Bouloux, Jensen, & Telfer, 1998). Among the mineral nutrients, Mg2+ is essential for physiological function in various tissues and organs.

    View all citing articles on Scopus
    View full text